Company Quick10K Filing
Golden Star Resource
10-Q 2020-12-31 Filed 2021-02-12
10-Q 2020-09-30 Filed 2020-11-16
10-K 2020-06-30 Filed 2020-09-28
10-Q 2020-03-31 Filed 2020-05-15
10-Q 2019-12-31 Filed 2020-02-12
10-Q 2019-09-30 Filed 2019-11-13
10-K 2019-06-30 Filed 2019-09-30
10-Q 2019-03-31 Filed 2019-05-13
10-Q 2018-12-31 Filed 2019-02-13
10-Q 2018-09-30 Filed 2018-11-13
10-K 2018-06-30 Filed 2018-09-28
10-Q 2018-03-31 Filed 2018-05-14
10-Q 2017-12-31 Filed 2018-02-13
10-Q 2017-09-30 Filed 2017-11-13
10-K 2017-06-30 Filed 2017-09-28
10-Q 2017-03-31 Filed 2017-05-12
10-Q 2016-12-31 Filed 2017-02-13
10-Q 2016-09-30 Filed 2016-11-16
10-K 2016-06-30 Filed 2016-09-28
10-Q 2016-03-31 Filed 2016-05-16
10-Q 2015-12-31 Filed 2016-02-16
10-Q 2015-09-30 Filed 2015-11-13
10-K 2015-06-30 Filed 2015-09-29
10-Q 2015-03-31 Filed 2015-05-15
10-Q 2014-12-31 Filed 2015-02-12
10-Q 2014-09-30 Filed 2014-11-14
10-K 2014-06-30 Filed 2014-09-26
10-Q 2014-03-31 Filed 2014-05-13
10-Q 2013-12-31 Filed 2014-02-10
10-Q 2013-09-30 Filed 2013-11-12
10-K 2013-06-30 Filed 2013-09-30
10-Q 2013-03-31 Filed 2013-05-14
10-Q 2012-12-31 Filed 2013-02-13
10-Q 2012-09-30 Filed 2012-11-15
10-K 2012-06-30 Filed 2012-09-26
10-Q 2012-03-31 Filed 2012-05-15
10-Q 2011-09-30 Filed 2011-11-10
10-K 2011-06-30 Filed 2011-10-11
10-Q 2011-03-31 Filed 2011-05-13
10-Q 2010-12-31 Filed 2011-02-08
10-Q 2010-09-30 Filed 2010-11-08
10-K 2010-06-30 Filed 2010-09-28
10-Q 2010-03-31 Filed 2010-05-07
10-Q 2009-12-31 Filed 2010-02-22

Golden Star Resource Financials

GLNS Metrics, Comps, Filings

Quarterly | Annual

Valuation ($)

Market Cap, Enterprise Value

Balance Sheet ($)

Assets, Equity

Income Statement ($ Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($ Quarterly)

Ops, Inv, Fin

Comps ($ TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
ENETI INC. (NETI)
024 Pharma (EEIG)
Vivus (VVUS) 40,869,120,000 77% -17.5 -11% 226,103,000,000 289,374,000,000 72,620,000,000 55,706,000,000 -24,956,000,000 -13,928,000,000 243,484,120,000
Clovis Oncology (CLVS) 219,222,100,000 0% -0.0 -56% 716,892,000,000 804,387,000,000 134,050,000,000 0 -400,184,000,000 -394,255,000,000 17,741,099,000
Cementos Pacasmayo Saa (CPAC) 4,145,433,431,000 0% 2,863,245,000,000 1,411,882,000,000 0 0 0 0 4,145,433,431,000
11 Good Energy (ELVN)
Exantas Capital (XAN)
1347 Capital Corp (TFSC)
Bancorp of New Jersey (BKJ) 122,881,100,000 1.0 0% 961,684,000,000 868,577,000,000 0 0 3,422,000,000 14,772,000,000 14,360,099,000
1PM Industries (OPMZ)
1st Century Bancshares (FCTY)
1st Financial Services Corp (FFIS)
1st United Bancorp (FUBC)
2-Track Global (TTG)
ENTERGY ARKANSAS, LLC (EAI)
21st Century Oncology Holdings (RTSX)
24Holdings (TWFH)
30DC (TDCH)
3D Pioneer Systems (DPSM)
ALABAMA POWER CO (APRCP)

Balance Sheet ($)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash11,0001,863,0001,550,000001,208,00028,000026,00040,0003,0002,0005,00034,00016,0004,00010,000065,00047,00032,00014,0006,0001,0006,00005,00068,00054,00040,00016,000280,000
Accounts Receivable
Inventory
PP&E
Assets11,0003,363,0003,050,0001,500,0001,500,0002,708,00028,000026,00040,0003,0002,00010,324,00034,00016,0004,00010,000065,0005,047,0002,032,0005,014,0002,006,0005,001,0002,006,0005,417,0002,171,0005,485,0002,221,0005,457,0002,183,0005,697,000
Accounts Payable
Long-Term Debt
Liabilities178,917,000208,042,000241,506,000270,722,000293,657,000323,166,000364,416,000382,570,000388,813,000398,056,000418,001,000424,867,000450,880,000471,558,000475,150,000475,150,000489,871,000503,865,000504,882,000507,875,000510,731,000519,542,000526,124,000535,902,000547,859,000558,383,000562,631,000571,709,000582,912,000592,505,000595,535,000612,840,000
Stockholders' Equity-178,906,000-204,679,000-238,456,000-269,222,000-292,157,000-320,458,000-364,388,000-382,570,000-388,787,000-398,016,000-417,998,000-424,865,000-440,556,000-471,524,000-475,134,000-475,146,000-489,861,000-503,865,000-504,817,000-502,828,000-508,700,000-514,528,000-524,118,000-530,901,000-545,853,000-552,966,000-560,460,000-566,224,000-580,691,000-587,048,000-593,352,000-607,143,000
Income Statement ($)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue000000000
Cost of Revenue
Gross Profit
R&D
SG&A4,500,0004,500,0004,500,0004,500,0004,500,0004,500,00004,500,0000000000
Tax0000
Net Income-23,368,000-25,773,000-33,777,000-30,766,000-21,135,000-28,301,000-43,930,000-18,182,000-24,399,000-9,229,000-19,982,000-6,867,000-15,690,000-30,969,000-3,610,000-12,000-13,965,000-14,068,000-952,0001,989,000-5,871,000-5,830,000-9,590,000-6,783,000-14,951,000-7,113,000-7,494,000-5,764,000-14,467,000-6,357,000-6,304,000-13,791,000
Cash Flow ($)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-10,171,000-15,990,000-7,558,000-3,954,000-7,929,000-3,471,000-28,000-2,543,000-528,000-5,012,000-11,962,000-13,986,000-19,409,000-3,108,000-590,000-14,714,000-14,400,0005,573,000-17,812,000-2,427,000-7,623,00027,803,000-5,0005,000-6,000-29,997,000-16,722,000-8,519,000-1,998,000-14,581,000
Cash Investing
Cash Financing12,023,00015,677,0006,008,0003,954,0009,137,0002,291,00002,540,000541,0004,976,00011,961,00013,989,00019,438,0003,089,000578,00014,720,00014,383,000-5,501,00017,794,0002,412,0007,605,00000030,002,00016,785,0008,505,0001,974,00014,845,000